Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Community-acquired pneumonia (CAP) triggers inflammatory and thrombotic host responses driving morbidity and mortality. Antiplatelet agents may favorably modulate these pathways; however, their role in non-COVID-19 CAP remains uncertain.
Objectives: To evaluate the association of antiplatelet agents with mortality in hospitalized patients with non-COVID-19 CAP.
Methods: We conducted a systematic review and meta-analysis of observational studies and randomized controlled trials (RCTs) of adult patients hospitalized for non-COVID-19 CAP exposed to antiplatelet agents (acetylsalicylic acid or P2Y12 inhibitors). We searched MEDLINE, Embase, and CENTRAL from inception to August 2023. Our primary outcome was all-cause mortality: meta-analyzed (random-effects models) separately for observational studies and RCTs. For observational studies, we used adjusted mortality estimates.
Results: We included 13 observational studies (123,012 patients; 6 reported adjusted mortality estimates) and 2 RCTs (225 patients; both high risk of bias). In observational studies reporting hazard ratio, antiplatelet agents were associated with lower mortality (hazard ratio, 0.65; 95% CI, 0.46-0.91; = 85%; 4 studies, 91,430 patients). In studies reporting adjusted odds ratio, antiplatelet agent exposure was associated with reduced odds of mortality (odds ratio, 0.67; 95% CI, 0.45-1.00; = 0%; 2 studies, 24,889 patients). Among RCTs, there was a nonsignificant association with mortality (risk ratio, 0.66; 95% CI, 0.20-2.25; = 54%; 2 studies, 225 patients). By the Grading of Recommendations, Assessment, Development, and Evaluation criteria, the certainty of the evidence was low, primarily due to risk of bias.
Conclusion: In hospitalized patients with non-COVID-19 CAP, antiplatelet agents may be associated with reduced mortality compared with usual care or placebo, but the certainty of evidence is low.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11387270 | PMC |
| http://dx.doi.org/10.1016/j.rpth.2024.102526 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk Factors for Incidental Durotomy in Initial Posterior Decompression Surgery for Lumbar Central Canal Stenosis with Bilateral Neurogenic Claudication.
World Neurosurg
September 2025
Department of Orthopaedic Surgery, The University of Tokyo 7-3-1, Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan; University of Tokyo Spine Group (UTSG), 7-3-1, Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan. Electronic address:
Objective: To identify significant risk factors for incidental durotomy (ID) in initial posterior decompression surgery for lumbar central canal stenosis and to explore whether these risks vary by surgical approach through subgroup analyses.
Methods: This study included patients who underwent single-level posterior decompression surgery for lumbar central canal stenosis with bilateral neurogenic claudication at eight hospitals between April 2017 and May 2023. Patient demographics, comorbidities, and surgical details, including surgeon certification status, were collected.
Vascular imbalance in polycystic ovary syndrome: Insights into endothelial dysfunction.
PLoS One
September 2025
Department of Biostatistics, Faculty of Medicine, Malatya Turgut Özal University, Malatya, Turkey.
Polycystic ovary syndrome (PCOS) is a multifactorial endocrine disorder associated with vascular dysfunction and increased cardiovascular risk. This study aims to investigate the dysregulation of vascular tone in PCOS, focusing on the imbalance between vasodilators (nitric oxide [NO] and apelin) and vasoconstrictors (noradrenaline and reduced prostacyclin). By examining these factors, the study seeks to elucidate their contribution to endothelial dysfunction and cardiovascular complications in PCOS patients.
View Article and Find Full Text PDFAvoiding Electrocautery: Hemostatic Agents for Perioperative Bleeding in Mohs Micrographic Surgery.
Dermatol Surg
September 2025
Epiphany Dermatology, Dallas, Texas.
Background: Bleeding remains a frequent complication during Mohs micrographic surgery, particularly among patients receiving anticoagulant or antiplatelet therapy. The growing use of these medications has prompted increased exploration of adjunctive methods to improve perioperative hemostasis.
Objective: To systematically review the literature on topically and locally administered hemostatic agents used to reduce bleeding in Mohs micrographic surgery.
Indobufen Versus Aspirin Plus Clopidogrel in Patients After Coronary Stenting in Patients With Diabetes: A Post Hoc Analysis of the OPTION Trial.
J Diabetes
September 2025
Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, National Clinical Research Center for Interventional Medicine, Shanghai, China.
Background: Despite increased risk of ischemic events in diabetes, the optimal anti-thrombotic strategy for secondary prevention has not been defined. We aimed to assess the efficacy and safety of optimal antiplatelet agents such as indobufen-based dual antiplatelet therapy (DAPT) in patients with diabetes after coronary stenting.
Methods: OPTION trial was a randomized, open-label, noninferiority, and multicentric study in China.
The effects of 5-HT on vascular endothelial dysfunction in patients with panic disorder.
Front Cardiovasc Med
August 2025
Department of Geriatrics, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Panic Disorder (PD) is a prevalent psychiatric condition characterized by recurrent episodes of acute severe anxiety. These episodes frequently present with symptoms that overlap with those of cardiovascular diseases (CVD), such as elevated blood pressure and chest pain. Despite the prevalence and impact of this comorbidity, the underlying mechanisms are not well understood and remain underexplored.
View Article and Find Full Text PDF